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Abstract
Background: Studies in the fmr1 KO mouse demonstrate hyper-excitability and increased high-frequency neuronal
activity in sensory cortex. These abnormalities may contribute to prominent and distressing sensory hypersensitivities in
patients with fragile X syndrome (FXS). The current study investigated functional properties of auditory cortex using a
sensory entrainment task in FXS.
Methods: EEG recordings were obtained from 17 adolescents and adults with FXS and 17 age- and sex-matched
healthy controls. Participants heard an auditory chirp stimulus generated using a 1000-Hz tone that was amplitude
modulated by a sinusoid linearly increasing in frequency from 0–100 Hz over 2 s.
Results: Single trial time-frequency analyses revealed decreased gamma band phase-locking to the chirp stimulus in
FXS, which was strongly coupled with broadband increases in gamma power. Abnormalities in gamma phase-locking
and power were also associated with theta-gamma amplitude-amplitude coupling during the pre-stimulus period and
with parent reports of heightened sensory sensitivities and social communication deficits.
Conclusions: This represents the first demonstration of neural entrainment alterations in FXS patients and suggests
that fast-spiking interneurons regulating synchronous high-frequency neural activity have reduced functionality. This
reduced ability to synchronize high-frequency neural activity was related to the total power of background gamma
band activity. These observations extend findings from fmr1 KO models of FXS, characterize a core pathophysiological
aspect of FXS, and may provide a translational biomarker strategy for evaluating promising therapeutics.
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Background
Fragile X syndrome (FXS) is the most common single-
gene cause of autism spectrum disorder with social anx-
iety and auditory hypersensitivity particularly common
[1–4]. Despite rapid growth in knowledge of molecular
mechanisms from KO mouse studies, there are no
known effective treatments for FXS. Development of
translational biomarkers that quantify neocortical corre-
lates of sensory sensitivity in FXS can facilitate drug dis-
covery by identifying non-invasive indicators of disease
pathology and track treatment response. EEG/event-re-
lated potential (ERP) studies, readily performed across
species, are a promising and relatively unexplored direc-
tion for this purpose in neurodevelopmental disorders
such as FXS.
Reduced local circuit inhibition has been proposed as
a neural mechanism for sensory hypersensitivity and
neural hyper-excitability in FXS [5–7]. Specifically,
gamma band activity has been associated with bottom-
up sensory processing of stimulus characteristics [8]
and primarily reflects local circuit GLU/GABA interac-
tions involving excitation onto and inhibition originat-
ing from parvalbumin positive (PV+) fast-spiking
interneurons [9, 10]. In Fmr1 KO mice, prolonged per-
sistent gamma activity or “UP” states have been
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associated with decreased glutamatergic drive onto fast-
spiking GABAergic inhibitory neurons in sensory cor-
tex [5, 6]. Further, network inhibition during UP states
is less synchronous, particularly in gamma frequencies.
Broadened high-frequency tuning curves suggestive of
increased nonspecific excitability also have been found
in Fmr1 knockout mice [7]. Prolonged asynchronous
UP states suggest that the ability to synchronize gamma
power may be specifically reduced, but simultaneously
net gamma power may be increased because of in-
creased nonspecific excitability in the gamma range.
These findings suggest a pattern of increased total
high-frequency (gamma) neural activity but reduced
temporally synchronous and spatially focused neural
activity that may have broad neurobehavioral implica-
tions in addition to its impact on sensory processing
[11]. Since gamma is the primary working frequency
range of the human auditory system, it is possible to in-
vestigate hypotheses generated by pre-clinical models
in a relatively non-invasive fashion in FXS using
auditory processing paradigms and EEG [12].
Our previous findings showed significantly increased
nonspecific gamma activity (gamma single-trial power)
in FXS that was associated with a decreased ability to
transiently synchronize evoked gamma (the “gamma
spike” during early stimulus registration) and to habitu-
ate the neural response to repeated tones [13]. Related
findings have been reported in Fmr1 KO mice [14]. Our
findings linking gamma power and sensory hypersensi-
tivities in FXS patients suggest a convergence with FXS
animal model findings of altered local inhibitory net-
works in and highlight the need for more systematic
study of gamma-band neural activity in FXS.
One previously unexplored strategy is to drive sensory
cortex with stimuli oscillating at gamma frequencies to
examine the ability to synchronize neural responses to
oscillating frequencies of sensory input. When presented
with an amplitude-modulated stimulus oscillating at a
certain frequency, neural networks oscillate in time with
the stimulus frequency, effectively increasing the signal-
to-noise ratio (SNR) for activity at that frequency in the
local cortical network and thus in the EEG signal. The
ability to “drive” cortical networks at desired frequencies
to evaluate their functional integrity is especially import-
ant when studying high frequencies such as gamma, as
neural oscillatory power is lower at high frequencies
[15]. Rather than studying a single frequency as in
steady-state examinations, a “chirp” stimulus that
increases linearly in frequency across the stimulus
presentation period enables the study of neural
synchronization across a broad range of input frequen-
cies in a short amount of time.
The current study utilized a chirp stimulus to evaluate
neural synchronization to sensory input across a range
of frequencies from 1 to 100 Hz. Although relatively
novel in neurophysiological research, chirp stimuli have
been used successfully to drive and examine neural ac-
tivity in the gamma frequency range in humans [16] and
rodents [17], and they have been demonstrated to be
sensitive to pharmacological manipulation [18]. We pre-
dicted that FXS patients would be less able to
synchronize neural networks oscillations to match the
chirp stimulus that such abnormalities would be most
pronounced in the gamma band and that this abnormal-
ity would be related to total background gamma power
and clinical reports of sensory hypersensitivities.
Methods
Participants
Seventeen adolescents and adults with full mutation FXS
(mean age = 26.2, SD = 11.8; age range 12–57; 4 females)
and 17 age- and sex-matched controls (mean age = 26.9,
SD = 10.9; age range 11–55; 4 females) participated in
the study (Table 1). While genetic effects of FXS are
more complex in females, we included females in pri-
mary analyses and confirmed effects in supplemental
analyses of male participants. Healthy controls had no
known prior diagnosis or treatment for neuropsychiatric
illness. Exclusion criteria included history of seizures
and current use of anticonvulsant medications including
benzodiazepines or novel potential treatments for FXS
(e.g., minocycline). Four patients were receiving atypical
antipsychotics (2 aripiprazole, 2 risperidone), two antide-
pressants, (paroxetine, citalopram) and one both an
atypical antipsychotic (aripiprazole) and an antidepres-
sant (citalopram), all on a stable dose for at least 4 weeks.
EEG studies of these drugs in psychiatric research sug-
gest they do not significantly alter electrophysiology in a
way that would confound data interpretation, consistent
with our analyses, which only found one difference in
EEG measures based on whether patients were taking
these psychiatric medications [19, 20].
The Adolescent and Adult Sensory Profile [21] and
the Social and Communication Questionnaire (SCQ;
[22]) were completed for FXS participants by their pri-
mary caregiver. IQ of FXS participants was assessed with
the Stanford-Binet Intelligence Scale 5th Ed. [23] which
has psychometric properties that enable characterization
of intellectual ability in lower-IQ individuals [24]. IQ of
controls was estimated using the briefer Wechsler
Abbreviated Scale of Intelligence [25]. Most FXS pa-
tients scored in the intellectually disabled range, with
four female patients scoring in the low-normal range;
EEG and clinical ratings did not differ for these patients,
and they were retained in primary analyses as planned.
Due to the preponderance of low IQ scores in the FXS
patients, deviation scores were also calculated for verbal
and nonverbal IQ using the technique proposed by
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Sansone and colleagues [24]. All participants provided
written informed consent (caregiver with assent or indi-
vidual consent as appropriate) prior to participation, as
approved by the UT Southwestern Institutional Review
Board.
Procedure
The auditory chirp stimulus used in the present study
consisted of a 1000-Hz carrier tone amplitude modu-
lated by a sinusoid linearly increasing in frequency
from 0–100 Hz over 2000 ms [16]. These were pre-
sented 200 times each separated by an inter-trial inter-
val randomly jittered between 1500 and 2000 ms.
Stimuli were delivered at 65 db SPL through head-
phones while participants underwent EEG. Participants
watched a silent movie to facilitate compliance as in
prior studies [13, 26].
ERP recording
EEG was continuously recorded and digitized at 512 Hz,
with a 5th-order Bessel anti-aliasing filter at 200 Hz,
using a 128 channel BioSemi ActiveTwo system
(BioSemi, Inc., Amsterdam, Netherlands) with sensors
placed according to the International 10/10 system [27].
All sensors were referenced to a monopolar reference
feedback loop connecting a driven passive sensor and a
common-mode-sense active sensor, both located on
posterior scalp.
EEG analysis
Raw data were visually inspected offline. Bad sensors
were interpolated (no more than 5% per subject) using
spherical spline interpolation implemented in BESA 6.0
(MEGIS Software, Grafelfing, Germany). Data were
digitally filtered from .5–120 Hz (12 and 24 db/octave
rolloff, respectively; zero-phase; 60 Hz notch) and re-
referenced to average reference. Eye movement, cardiac,
and muscle movement artifacts were removed blind to
participant group using independent components ana-
lysis (ICA; Infomax) implemented in EEGLAB 11 [28] in
Matlab (The Mathworks, Natick, MA). Data were
epoched into 3500 ms trials (−500 to 3000 ms), averaged
across trials and baseline-corrected using the 500-ms
pre-stimulus period. Any trial with post-ICA amplitude
exceeding 100 μV was considered residual artifact and
removed prior to averaging. Number of valid trials did
not differ between groups (FXS M = 166.5, SD = 29.1;
Control M = 179.1, SD = 17.9, t(32) = 1.5, p = .14).
To take advantage of the dense electrode array and in-
tegrate data from every sensor, spatial principal
components analysis (PCA) was implemented on the
grand average ERP [29, 30]. PCA solutions were corre-
lated r = .99 between groups, so the grand average ERP
solution collapsed across group was retained. Compo-
nent weights were multiplied by each subject’s average
data, summed across sensors, and divided by the sum of
the component weights, reducing waveforms from one
for each sensor to one waveform per component with a
defined spatial distribution across the scalp (Fig. 1).
Spatial PCA revealed a single spatial component repre-
senting 85.3% of the variance that was consistent with
known topographies representing signal from auditory
cortex (Fig. 1). Subsequent analyses were performed on
a virtual sensor created by weighting trial-wise EEG data
by the PCA component weights.
PCA-weighted un-baseline-corrected epoched single-
trial data were analyzed in the time-frequency domain
using Morlet wavelets with 1-Hz frequency steps using a
linearly increasing cycle length from 1 cycle at the low-
est frequency (2 Hz) to 30 cycles at the highest (120 Hz).
Single-trial power (STP) and inter-trial coherence (ITC)
measures obtained from this method evaluated the amp-
litude of response at each frequency and how stable or
phase-locked responses were to the auditory stimuli
Table 1 Participant characteristics
FXS n = 17 Controls n = 17
Mean Std. dev. Range Mean Std. dev. Range t statistic (df)
Age 26.2 11.8 12–57 Age 26.9 10.9 11–55 t(32) = 0.2, p = .86
Full scale IQ 55.6 16.3 47–94 Full scale IQ 104.8 13.7 82–123 t(32) = 9.5, p < .001
Verbal (scaled) 2.8 3.5 1–11 Verbal 107.4 11.5 90–125
Nonverbal (scaled) 2.1 2.1 1–7 Performance 108.6 10.8 89–124
Deviation IQ Deviation IQ
Verbal −3.4 1.8 −5.5–.15 Verbal – – –
Nonverbal −4.7 2.2 −8.2– −1.2 Performance – – –
SCQ 21.8 6.7 14–31 SCQ 4.4 4.6 1–17 t(22) = 7.5, p < .001
Sensory profile 32.1 10.1 18–46 Sensory profile 22.6 4.9 16–30 t(21) = 3.2, p = .004
IQ assessed by Stanford-Binet in FXS and estimated using the Wechsler Abbreviated Scale of Intelligence (WASI) in healthy controls. Deviation IQ is only recommended
for assessing floored subscale score IQ values for the Stanford-Binet based on population statistics provided for public use by the publisher; therefore, deviation IQ
measures are not available for the healthy controls. SCQ Social and Communication Questionnaire
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across trials, respectively [27]. Raw ITC values were ini-
tially corrected for trial number by subtracting the crit-
ical r value [1/sqrt (number of trials)] for each subject
based on trial count. STP and ITC values were averaged
over trials for each individual and transformed into
time-frequency plots down-sampled to 250 time-bins.
Statistical analysis
For stimulus-related EEG analyses, point-by-point two-
tailed t tests were used to calculate group differences
across the time-frequency matrix. Time-frequency clus-
tering techniques and Monte Carlo simulations con-
trolled for multiple comparisons [29, 31]. To maintain a
family-wise alpha of p < .01 (corrected for multiple com-
parisons), a minimum of three sequential time-bins and
three adjacent frequencies were required to be signifi-
cant at a nominal threshold of p < .05. STP was analyzed
both without baseline correction (Fig. 2a) and secondar-
ily with baseline correction applied for each frequency
(Fig. 2b).
For pre-stimulus analyses, the same component
weights were applied to the pre-stimulus period in order
to analyze pre-stimulus activity from the same PCA-
defined topographical area in which stimulus-related ac-
tivity occurred. Theta and alpha band modulation of
gamma activity were of particular interest, as previous
studies have suggested theta and alpha abnormalities in
FXS patients [32, 33] and KO rodent models [34]. Fre-
quency bands of interest were chosen as follows based
on standard low-frequency and gamma band cut-offs:
theta, 4–7 Hz; alpha, 8–12 Hz; gamma, 30–80 Hz. Add-
itional analyses on delta and beta frequency bands are
presented in Additional file 1. Coupling of low-
frequency oscillations (theta, alpha) with higher-
frequency oscillations (gamma) in the pre-stimulus
period were evaluated to assess top-down modulation of
gamma activity in local cortical networks during prepar-
ation for stimulus processing [35–37]. For amplitude-
amplitude coupling analyses, for each participant, ampli-
tude of baseline single-trial pre-stimulus data (from
−1000 to −50 ms pre-stimulus, padded to avoid window-
ing effects) was calculated as the average amplitude
(absolute value of the complex wavelet result) within a
trial and within each frequency band of interest. Average
amplitude was then correlated across trials for each low-
frequency amplitude measure of interest (theta, alpha)
with the amplitude of high-frequency power (gamma).
Correlation coefficients were z-transformed across all
participants and then compared between groups.
For phase-amplitude coupling analyses, instantaneous
phase and amplitude in each frequency band were calcu-
lated from the Hilbert transformed data using the
Phase-Amplitude Coupling Toolbox (PACT) for
EEGLAB [38]. Trial data was concatenated for each indi-
vidual to calculate overall pre-stimulus phase-amplitude
coupling. Modulation index [39], a measure of cross-
frequency phase-amplitude coupling, and mean resultant
vector length, a measure of phase consistency in low fre-
quencies across windows of time with the highest ampli-
tude of gamma, were calculated according to standard
methods within the toolbox (36 phase bins, top 2% of
gamma amplitudes analyzed; [38]). Modulation index is
sensitive to amplitude, which may differ between groups
[13], whereas mean resultant vector length is normalized
Fig. 1 Example averaged virtual channel created by weighting the grand average epoched EEG data by the spatial PCA component, with inset
PCA spatial component topography. Chirp stimulus amplitude modulation and timing is presented below. Note the increase in oscillation
frequency in the PCA component waveform that matches the increase in chirp modulation frequency in the stimulus below
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to [0 1]; therefore, mean resultant vector length was
used for group comparisons. To be comprehensive and
facilitate comparison with prior work, both measures
were included in clinical correlation analyses.
Clinical correlations were examined with all signifi-
cant time-frequency clusters. We also examined
hypothesis-driven associations between gamma STP
and gamma ITC. To examine whether pre-stimulus
activity was associated with evoked response parame-
ters of interest, pre-stimulus amplitude-amplitude and
amplitude-phase coupling measures were correlated
with gamma STP and gamma ITC during tone pro-
cessing. All correlations were conducted using
Spearman’s rho. Clinical correlations with sensory and
social abnormalities (Sensory Profile, SCQ), age, and
deviation IQ are presented as exploratory and hypoth-




Point-by-point t tests on time-frequency plots for ITC
and STP (corrected for multiple comparisons) revealed
10 time-frequency clusters with significant differences
between FXS and controls (Fig. 2, Table 2). Cluster
names are identified by timing relative to stimulus onset
and frequency band, which provides equivalency with
the X and Y axes in Fig. 2. Cluster peaks were identified
using the highest t values reflecting group differences,
not peaks of activity. For absolute gamma STP, a peak
statistic is reported; however, group differences in
gamma power were remarkably stable throughout the
trial including before, during, and after stimulus presen-
tation. FXS patients showed significantly increased
phase-locking in alpha frequencies during the stimulus
onset time period and decreased theta frequency phase-
locking and increased alpha frequency phase-locking
Fig. 2 a Single trial power (STP) for controls, FXS, and difference maps (FXS minus controls). b Baseline corrected single trial power (STP) for
controls, FXS, and difference maps (FXS minus controls). c Inter-trial coherence (ITC) for controls, FXS, and difference maps (FXS minus controls).
Black boxes in the difference maps indicate clusters with significant group differences. Warmer colors (reds, yellows) in the difference maps (right
column) indicate higher phase-locking or higher power for FXS, and cooler colors (blues, greens) indicate higher values for healthy controls
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after stimulus offset (Fig. 2c), consistent with
increased ERP amplitudes found in previous work
[40, 41]. As expected, FXS showed decreased gamma
phase-locking to the chirp stimulus from 30–58 Hz
and decreased gamma phase-locking to the chirp har-
monic from 47–58 Hz (Fig. 2a) as well as a decreased
ability to increase gamma power above the already
elevated baseline (Fig. 2b).
Cross-frequency amplitude-amplitude and phase-
amplitude coupling analyses during the pre-stimulus
period when participants were awaiting the next chirp
stimulus revealed that control subjects showed a positive
cross-frequency amplitude-amplitude coupling between
all low frequencies and gamma. FXS showed significantly
less amplitude-amplitude coupling between alpha and
gamma, t(32) = 2.5, p = .02, compared to controls. There
were no group differences in theta-gamma amplitude-
amplitude coupling or in the phase-amplitude coupling
measures. Coupling measures were analyzed for low
(30–50 Hz) and high (65–80 Hz) gamma separately, but
results did not differ so this band was collapsed for final
analyses.
Gamma power and phase-locking
Although there were no group differences in number of
artifact-free trials retained, gamma STP and ITC were
negatively correlated with valid trial number in both
controls and FXS. Therefore, these variables were cor-
rected for trial number by subtracting the product of the
linear regression coefficient for controls and trial num-
ber [42]. Trial-adjusted correlations remained significant;
rho values reflect the adjusted values. For FXS, increased
gamma single trial power was correlated with decreased
gamma phase-locking to the chirp stimulus (rho = −.83,
p < .001) and to its harmonic (rho = −.78, p < .001). In-
creased gamma power in FXS can be characterized as an
increase in background neural “noise,” reducing overall
signal-to-noise ratio (SNR) of sensory processing in the
auditory cortex. This association between increased non-
specific high-frequency neural activity and decreased
ability to synchronize gamma frequency activity is con-
sistent with our previous reports from an auditory
habituation task and during the resting state, but made
more apparent by its relation to the gamma neural
entrainment alterations during the chirp task.
Increased pre-stimulus theta-gamma amplitude
coupling was correlated with increased gamma STP
(rho = .55, p = .02) and decreased gamma phase-locking
to the chirp (rho = −.69, p = .002) and the chirp
harmonic (rho = −.63, p = .007).
Clinical correlations
Significant correlations with clinical measures in FXS
participants are presented in Table 3. Of particular inter-
est, increased gamma power and reduced phase-locking
to the chirp were significantly related to clinical ratings
of both sensory hypersensitivities and autism spectrum
social/behavioral features, respectively. Gamma STP was
higher in medicated patients, t(15) = 2.8, p = .01. It is not
possible to determine whether psychiatric medications
were causing EEG alterations or if the medications were
prescribed to treat particularly severe behavioral prob-
lems associated with the EEG alterations (medicated pa-
tients also had more abnormal clinical ratings on the
Sensory Profile and SCQ—p < .01). However, in studies
of multiple psychiatric disorders, gamma power remains
Table 2 Time-frequency clusters with significant group differences
Cluster label Time range Peak time Peak frequency Statistic Direction of group difference
Phase-locking (ITC)
Stimulus onset alpha 252 to 430 ms 288 ms 13 Hz t(32) = 3.4, p = .002 FXS > CON
Stimulus offset theta 1883 to 2049 ms 1966 ms 3 Hz t(32) = 3.62, p = .001 CON > FXS
Stimulus offset alpha 2084 to 2214 ms 2178 ms 9 Hz t(32) = 3.20, p = .003 FXS > CON
Chirp 607 to 1068 ms 761 ms 42 Hz t(32) = 2.8, p = .008 CON > FXS
Chirp harmonic 382 to 631 ms 406 ms 50 Hz t(32) = 2.9, p = .007 CON > FXS
Single trial power
Overall gamma −220 to 2722 ms 819 ms 57 Hz t(32) = 2.8, p = .008 FXS > CON
Baseline corrected single trial power
Stimulus onset alpha 229 to 335 ms 276 ms 11 Hz t(32) = 3.0, p = .005 FXS > CON
80 Hz 855 to 2462 ms 914 ms 82 Hz t(32) = 3.0, p = .005 CON > FXS
110 Hz stimulus onset 300 to 619 ms 572 ms 112 Hz t(32) = 3.0, p = .005 CON > FXS
110 Hz late 1647 to 2462 ms 2261 ms 112 Hz t(32) = 3.1, p = .005 CON > FXS
Cluster names are identified by stimulus association and frequency band. Time ranges are given relative to initial stimulus onset, to provide equivalency with the
X axes in Fig. 2. Cluster peaks are identified for highest t values, not for peaks of activity. For overall gamma single trial power, a peak statistic is reported;
however, it should be noted that group differences were remarkably stable throughout the time period
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relatively unaffected in patients treated with these medi-
cations [19, 20]. FXS patients showed a significant cor-
relation between age and gamma ITC during the ERP to
stimulus onset (rho = .59, p = .01) and age and theta ITC
during the ERP to stimulus offset (rho = .52, p = .03),
while these correlations were not significant in the age-
matched controls. Controls showed significant age cor-
relations for theta-gamma phase amplitude coupling
(modulation index: rho = −.61, p = .009; vector length:
rho = −.53, p = .03) that were not reflected in FXS.
Discussion
The current study utilized a neural entrainment
approach for the first time in FXS to selectively drive
networks oscillators in auditory cortex to clarify the ex-
tent of hypothesized deficits in local circuit inhibition in
FXS. FXS patients demonstrated a marked reduction in
the ability to synchronize (phase-lock) high-frequency
neural activity to the chirp stimulus as well as the first
harmonic (doubling of chirp frequency) suggesting im-
pairments in the synchronization of networks at the pri-
mary and secondary levels of sensory processing. Both
phase-locking abnormalities were highly associated with
increased nonspecific gamma power, providing new
evidence for a robust functional link between increased
local network excitation reflected in raw gamma power
and decreased ability to synchronize high-frequency
population-level neural activity in sensory networks. The
combination of deficits in entrainment coupled with
hyper-excitation was specific to gamma, which coincide
with highly selective deficits in neural synchronization
related to local network excitation/inhibition balance
previously identified in FXS translational models and
proposed to underlie core clinical deficits in FXS [5, 43].
Increased desynchronous high-frequency firing or
“noise” (gamma STP) and decreased synchronized
gamma activity to a driving stimulus indicate that both
factors contribute to an overall worsening of auditory
cortex SNR during sensory processing in FXS. FXS pa-
tients were also unable to selectively increase gamma
power above baseline compared to controls, possibly in-
dicating that ongoing gamma power is saturated.
Decreased SNR reflecting heightened neocortical excit-
ability suggests a plausible mechanism for the highly
prevalent sensory hypersensitivity found in individuals
with FXS. Indeed, increased gamma STP was correlated
with parental reports of increased auditory hypersensi-
tivity. Increased gamma STP was also associated with
autism-associated social impairment using the SCQ, sug-
gesting that cortical hyper-excitability may have broader
clinical impact on behavior rather than selectively
impacting sensory systems. We speculate that coherent
high-frequency inhibitory network interactions play a
crucial role in defining receptive fields that are import-
ant for sensory, perceptual, and cognitive processes.
Recent work in Fmr1 KO rodent models have shown a
shift toward lengthened activation states and decreased
synchronization of fast-spiking interneuron-to-excitatory
cell networks in visual cortex [44] and reduced cross-
frequency gamma coupling in hippocampus [34], sug-
gesting that fast-spiking interneuron alterations findings
may not be restricted to a specific sensory modality but
may represent a more widespread neocortical abnormal-
ity. Because of the potential for an alteration in bottom-
up information processing to cause a wide range of
neurobehavioral symptoms, high-frequency neural activ-
ity may also represent an important treatment target for
alleviating multiple behavioral and sensory abnormalities
in FXS.
To investigate whether ongoing network oscillatory
properties contributed to decreased sensory system SNR
in FXS, we examined amplitude-amplitude and phase-
amplitude coupling between low frequencies and gamma
activity during the pre-stimulus period before chirp
presentation. Similar to findings in Fmr1 KO mouse cor-
tex [34], we found a shift toward reduced influence of
alpha frequency oscillations on gamma power and
synchronization in FXS compared to controls. Cortical
networks in healthy controls generally utilize alpha
oscillations to control and inhibit local network excita-
tion [45]; in FXS, these networks may rely more
consistently on slower theta waves or even delta waves
(see Additional file 1) to modulate gamma frequency,
given the lack of deficit in theta-gamma coupling. This
Table 3 Significant clinical correlations with EEG findings for FXS patients
EEG measure Clinical scale
Sensory profile—auditory SCQ total score Deviation score: nonverbal IQ
ITC chirp NS −.74* NS
STP gamma .61* .84** NS
Pre-stimulus theta/gamma amp-amp coupling NS .74* NS
Pre-stimulus theta/gamma phase amplitude coupling—vector length NS NS .58*
EEG measures with no significant correlations to clinical variables are not included. All correlations are Spearman’s rho. All correlations represent the FXS group
only. NS Not significant
*p < .05
**p < .01
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strategy may have some success, given the moderate
correlation between increased theta-gamma phase-
amplitude coupling and higher nonverbal deviation IQ
(Table 3) and the moderate correlation between delta-
gamma amplitude-amplitude coupling and more nor-
malized gamma power and phase-locking (Additional
file 1), but it may be a less successful alternative and one
with potential adverse sequelae on higher order neuro-
behavioral processes dependent on phasic delta/theta
modulation, including processes associated with ASD-
like behaviors (see Additional file 1: Table S2). This shift
may also account for increases in theta power and con-
nectivity seen in resting EEG in FXS [32, 33, 46], in-
creased gamma abnormalities during the chirp and
increased pre-stimulus theta-gamma coupling.
We also identified increases in alpha frequency phase-
locking during stimulus onset and offset and a decrease
in theta frequency phase-locking synchronous with
stimulus offset in FXS compared to controls. The in-
creased alpha phase-locking is consistent with previous
findings of increased amplitude early ERP components
in response to brief auditory stimuli in FXS [26, 40, 41].
Decreased theta frequency phase-locking simultaneous
to stimulus offset is a novel finding in FXS. Given the
role of theta-gamma coupling in network inhibition, this
theta burst at stimulus offset for healthy controls may
represent activation to prepare for the inhibition re-
quired to stop the gamma oscillations when the chirp
stimulus stops, a mechanism which may be deficient in
FXS.
Preclinical work in Fmr1 knockout mice has related
increased gamma excitability to decreased excitatory
drive on fast-spiking inhibitory interneurons, resulting in
increased and poorly synchronized pyramidal cell firing
in the gamma range [5]. Decreased activation of fast-
spiking inhibitory interneurons, which synchronize
gamma activity via projections from inhibitory neurons
onto multiple pyramidal neurons, has been proposed as
a mechanism for heightened neocortical excitability in
FXS [5]. Poorly organized inhibitory drive onto pyram-
idal cells in auditory cortex from fast-spiking interneu-
rons that control gamma synchronization could account
for the pattern we observed of increased gamma power,
suggesting increased high-frequency firing of excitatory
pyramidal neurons (noise) but with less coherent
organization (phase-locking) in response to sensory
stimulation. This pattern of alterations may contribute
to previously reported decreases in transient gamma
phase-locking [13]. Given the similar network dynamics
observed in Fmr1 rodent models [5, 7, 14, 44], findings
reported here may not only extend mouse model con-
cepts to FXS patients, but suggest that neurophysio-
logical measures may be useful for tracking this local
circuit deficit in both mouse models and patients to
foster direct translational drug development for this neu-
rodevelopmental disorder.
Certain study limitations should be considered. First,
comparative work is necessary to determine the degree
to which our findings occur in other neurodevelopmen-
tal disabilities, several of which have associated sensory
sensitivities as seen in FXS [47]. While evidence exists
for impaired phase-locking ability, increased power, and
alpha-gamma phase-amplitude coupling abnormalities in
other disorders such as ASD [48–50], these studies pri-
marily describe broad-band power abnormalities and
phase-locking deficits, whereas the most salient abnor-
malities in FXS were seen in the gamma band (but see
[51] for gamma deficits in very young boys with ASD).
Berman et al. [52] also report increased alpha-gamma
phase-amplitude coupling in children with ASD, an ef-
fect not replicated in FXS, although whether these differ-
ences are due to the clinical population or the age of the
participants is unknown. Intellectual disability (ID) asso-
ciated with FXS may also play a role in group differ-
ences, suggesting a role for these findings in other
disorders associated with ID. A pattern of low-frequency
power enhancement at rest has been primarily reported
in ASD only for those with ID [52]. A shift from alpha
to theta band activity has been reported in Down’s syn-
drome [53]; however, increased theta activity in children
with ADHD is robust in low- and high-IQ individuals
[54]. Decreased or normal gamma power in individuals
with ID is more commonly reported than the increased
power seen in FXS [55, 56]. Comparative studies be-
tween FXS and other forms of ID will determine the
specificity of the high-frequency disruptions reported
here and their relation to low-frequency function. Sec-
ond, FXS participants were taking various psychiatric
medications, and their potential impact on the data can-
not be ruled out. However, excluding medicated patients
necessarily excludes a subsample with more severe be-
havioral problems limiting study representativeness, and
the medications are well studied in psychiatric popula-
tions without known effects as we observed in our pa-
tients. Third, our failure to detect gender differences
should be considered in the context of the limited num-
ber of FXS female participants. Analyses of the male par-
ticipants were largely consistent with the findings in the
full sample, but future studies with larger samples of fe-
male participants should clarify gender differences in pa-
tients with FXS. Lastly, future research is needed to
investigate the sensory and perceptual consequences of
the identified neurophysiological alterations.
Conclusions
Despite extensive progress in understanding the genetic
alteration resulting in FXS and its biochemical and local
circuit functional consequences, far more modest
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advances have occurred in disease understanding at the
systems neuroscience level in affected individuals [57].
Further, no treatments have demonstrated clinical effi-
cacy for FXS, and translation from rodent models to hu-
man pharmacology has been constrained by a lack of
translational biomarkers to evaluate, predict, and under-
stand drug response. The current study provides novel
evidence that alterations in synchronous activity in fast-
spiking inhibitory interneurons, widely reported in trans-
lational models of FXS, may contribute to important
neurophysiological alterations which are measurable at
the systems level in humans with FXS and are of clinical
relevance. Our previous data showed decreased gamma
network inhibition in evoked responses during habitu-
ation to repeated stimuli [13] and increased resting
gamma power [33]. Our current report indicates altered
gamma-band neural entrainment to oscillatory chirp
stimuli which parallel preclinical findings in Fmr1 KO
rodent slice preparation [8] and evoked electrophysi-
ology research [14, 44]. Our results indicate that abnor-
malities in sensory neurophysiology not only are
clinically relevant but may be useful for in vivo studies
of FXS patients to track alterations in fast-spiking cell
populations known to be altered in KO mouse models
as a biomarker for predicting and evaluating response to
novel therapies. Although additional investigations of
test-retest reliability, task effects such as stimulus and
ISI length, age effects, and sex effects are warranted,
gamma deficits may serve as biologically grounded and
clinically relevant outcome measures in future clinical
trials for FXS.
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